Leukemia, Lymphoid Clinical Trial
Official title:
Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Blinatumomab Maintenance Treatment
The goal of this observation study is to test in relapsed or refractory acute lymphoblastic leukemia (R/R ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is: • Effect of post-transplant blinatumomab treatment on immune reconstitution after transplantation. Participants will undergo immune repertoire sequencing(IR-SEQ) before blinatumomab treatment, 6 months and 1 year after transplantation. Researchers will compare patients who don't receive blinatumomab treatment after transplantation to see if TCR or BCR expression differs.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT06111625 -
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
|
Phase 2 | |
Not yet recruiting |
NCT06075238 -
Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT
|
Phase 2 | |
Active, not recruiting |
NCT04849416 -
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
|
Phase 2 | |
Completed |
NCT00339664 -
Analyses of Human Samples Collected in Clinical Trials
|
||
Completed |
NCT01116193 -
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT00569179 -
A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies
|
Phase 1 |